Zalfermin and semaglutide have beneficial effects liver histology and fibrotic gene in a murine model of NASH
The potential clinical benefits of FGF21 analogues for the treatment of NASH has evolved significantly within the last years. However, despite clinical meaningful effect on NASH resolution and fibrosis the body weight loss in humans have been less impressive. Thus, a combination of an FGF21 analogue with a GLP-1 receptor agonist may add additional benefit to the treatment of NASH due to complimentary mode of action compared to stand alone therapies Overall design: RNA-sequencing data. CHOW diet: Vehicle n=8; AMLN diet: Vehicle  n=8, AMLN diet:  Zalfermin low dose (n=8), high dose  (n=8); Semaglutide low dose (n=8, one sample highlighted excluded during quality control)   high dose (n=8). Combination Zalfermin high and Semaglutide high (n=8).